References
- Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infiiximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008;18:460–4.
- Ishikawa H. The clinical usefulness of mizoribine for rheumatic diseases. BIO Clinica. 1999;14:376-9. (in Japanese).
- Ichinose K, Ida H, Kawakami A, Tsukada T, Ueki Y, Eguchi K, et al. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med. 2010;49:2211–8.
- Nishimura K, Nishino J, Kouchi A, Nakamura N, Nakajima S, Yokoe I, et al. Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose. Mod Rheumatol. 2011;21:158–63.
- Tanaka H, Suzuki K, Nakahata T, Sato T, Ito E. Mizoribine oral pulse therapy for a patient with severe lupus nephritis. Pediatr Int. 2003;45:488–90.
- Nozu K, Iijima K, Kamioka I, Fujita T, Yoshioka K, Tanaka R, et al. High-dose mizoribine treatment for adolescents with sys-temic lupus erythematosus. Pediatr Int. 2006;48:152–7.
- Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, et al. High-dose mizoribine therapy for childhood-onset fre-quently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744–9.
- Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28:3643–8.
- Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274: 87–92.
- Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical effi-cacy. Mod Rheum. 2007;17:206–12.
- Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006;16:214–9.